Abeona Therapeutics Inc ABEO

US Biotechnology

$2.46 ▼ -3.15% ($-0.08)

🔥 High Short Interest 📅 Earnings This Week

Open $2.60

Prev Close $2.54

Day Range $2.39 – $2.66

52W Range $2.30 – $7.65

Market Cap $145.25M

P/E (TTM) 2.15

Beta 1.68

EPS (TTM) $-1.12

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1980-09-19
Shares Out.	57,180,000
Website	abeonatherapeutics.com ↗
Phone	13026587581
Employees	226
Revenue	$11.4M
Gross Profit	$7.2M
Net Income	-$20.2M
Free Cash Flow	-$81.5M
Total Assets	$179.5M
Total Liabilities	$51.4M
Equity	$128.1M

About Abeona Therapeutics Inc

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Abeona Therapeutics Inc is a publicly traded company under the ticker symbol ABEO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.